A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous Administration of HS-20136-2 Injection in Healthy Participants
Latest Information Update: 30 Mar 2026
At a glance
- Drugs HS-20136-2 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 30 Mar 2026 New trial record